NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
Clinical Trials
13 trialsNCT04253561 2026-03-16
IPATHER
SOLTI Breast Cancer Research Group
Phase 1 Completed
NCT03280563 2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2 Completed
NCT03959891 2025-09-29
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT05332561 2025-03-20
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
German Cancer Research Center
Phase 2 Recruiting
NCT04060862 2024-11-08
IPATunity150
Hoffmann-La Roche
Phase 1 Terminated
NCT03395899 2024-06-18
ECLIPSE
Queen Mary University of London
Phase 2 Completed
NCT04177108 2024-03-27
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT03337724 2024-03-12
IPATunity130
Hoffmann-La Roche
Phase 3 Completed
NCT03840200 2023-10-30
A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Hoffmann-La Roche
Phase 1 Completed
NCT04920708 2023-10-27
FAIM
Royal Marsden NHS Foundation Trust
Phase 2 Recruiting
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT02301988 2018-10-17
A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer
Genentech, Inc.
Phase 2 Completed